

# Patient Preferences Study: Our Contribution as a Patient Organisation

ISPOR Europe

Copenhagen, 14 November 2023



Maria Stella De Rocchis  
Project Coordinator



## About EFCCA

**The European Federation of Crohn's & Ulcerative Colitis Associations (EFCCA) represents 46 national Crohn's and Ulcerative Colitis patient associations.**

**Our mission is to improve the life of over 10 million people (3.4 million in Europe alone) with Crohn's disease and Ulcerative Colitis (IBD) and to give them a louder voice and more visibility.**

“We believe that patients should be given  
**the best possible treatment options**  
not only in quality of care but also  
quality of life, allowing them  
to **live their life to the fullest.**”

Which are the **benefits** of  
incorporating **patient preferences**  
throughout the product life-cycle?



(polling question)



## Benefits

- The development of treatments and therapies that **better meet patients' needs**
  - ▶ Improved treatment outcomes and quality of life for patients
- The development of **safer and more effective** treatments
  - ▶ Potential risks and side effects can be addressed early on



## Benefits

- To bridge the gap **between patients and researchers**, fostering a sense of partnership and shared responsibility
  - ▶ Patients are empowered and valued, leading to increased trust and collaboration
- Treatments that are more likely to be **accepted and adhered to** by patients
  - ▶ Less time and resources on treatments that may not meet patient needs



## Facing PPS challenges

- Facilitating the **dialogue** between researchers and patients / Establishing **trust** between patients and researchers

### How we addressed this:

- Inclusion since the initial stages of the study / Partnership at the same level
- Communication clear and understandable
- Close collaboration among EFCCA, KU Leuven and IBD Patients



## Facing PPS challenges

- Ensuring a **patient-friendly survey language** for broad understanding, attributes and levels are **meaningful and relevant** to patients

### How we addressed this:

- Alternative vocabulary / Simplified language
- Understandability of questions and attributes at each stage
- Medical vs patient friendly terms





## Facing PPS challenges

- Understanding patient community **needs and concerns**, accounting for age, personal traits, and location variances

### How we addressed this:

- Survey translated into 14 different languages
- Personal / medical experience brought into the study design
- Participation in pilot, recruitment: patient organisations + clinicians



## How to maximize findings

- Findings will help us to achieve a general picture on the patient preferences at European level and analysing country data for comparison on how to support patients in clinical practice
- Results are helpful to standardise clinical trial protocols, support sponsors in achieving this goal, create standard guidelines



## How to maximize findings

- In the same direction, EFCCA is committed **to offer** the IBD community:
  - ▶ **Trainings** to provide with targeted education, competence, and information in order to **improve knowledges** around the disease and to **better advocate**
  - ▶ **Practical toolkit** on how to assist sponsors and health authorities in bringing **new medicines** to the market and making **better decisions**



# Patient Preferences Study



## Q&A

Can you tell us more about the last two examples of empowerment efforts that EFCCA is implementing?

# Patient Preferences Study



# Any questions?

[mariastella.derocchis@efcca.org](mailto:mariastella.derocchis@efcca.org)



# Thank you!

